Abstract:
Die Erfindung betrifft neuartige biokatalytische Prozesse, umfassend die Ganzzell-Reduktion von Dehydrocholsäure(DHCS)-Verbindungen, neuartige 7ß-Hydroxysteroid Dehydrogenase-Mutanten, die für diese Enzym-Mutanten kodierenden Sequenzen, Verfahren zur Herstellung der Enzym-Mutanten und deren Verwendung bei enzymatischen Umsetzungen von Cholsäureverbindungen, und insbesondere bei der Herstellung von Ursodesoxycholsäure (UDCS); Gegenstand der Erfindung sind auch neuartige Verfahren zur Synthese von UDCS unter Verwendung der Enzym-Mutanten; sowie insbesondere ein weiter verbessertes Verfahren zur Herstellung von UDCS unter Verwendung rekombinanter Ganzzell-Biokatalysatoren.
Abstract:
Die vorliegende Erfindung betrifft ein Verfahren zur Stabilisierung eines Enzyms durch Lagerung des Enzyms in Gegenwart eines stabilisierten Coenzyms. Weiterhin betrifft die vorliegende Erfindung ein mit einem stabilisierten Coenzym stabilisiertes Enzym sowie dessen Verwendung in Testelementen zum Nachweis von Analyten.
Abstract:
In some embodiments, the present invention provides a protein comprising amino acids in the following sequence L(X) n=14 X 3 (X) n=1 X 1 (X) n=1 E(X) n=4 P(X) n=1 NR(X) n=3 S(X) n=4 D(X) n=2 G(X) n=7 Y(X) n=4 Y (X) n=32-34 X 2 , wherein each X independently represents any naturally occurring amino acid residue and n indicates the number of amino acid residues represented by the respective paranthetical at that position, wherein: a) X1 is selected from the group consisting of S, C, T, M, V, Y, N, P, L, G, Q, A, I, D, W, H, or E, wherein if X 1 is L, H or V, then X 3 is D; and/or b) X 2 is selected from the group consisting of H, L, S or V. In some embodiments, the present invention also provides a protein comprising amino acids in the sequence set forth by SEQ ID NO: 38 or SEQ ID NO: 39, except that: the amino acid at position 406 is an amino acid other than F; and/or the amino acid at position 474 is an amino acid other than N.
Abstract:
Die Erfindung betrifft einen Produktionsstamm zur Herstellung von 2, 3-Butandiol. Dieser ist herstellbar aus einem Ausgangsstamm und weist unter Bedingungen der 2, 3-Butandiolproduktion eine Glucose Dehydrogenase Enzymaktivität auf, die im Ausgangsstamm nicht oder nur unter physiologischen Bedingungen die verschieden von den Bedingungen der 2, 3-Butandiolproduktion sind, vorhanden ist. Die Erfindung betrifft ferner ein Verfahren zur fermentativen Herstellung von 2, 3-Butandiol (2, 3-BDL) mittels eines derartigen Produktionsstammes.
Abstract:
The invention relates to novel biocatalytic processes, comprising the whole cell reduction of dehydrocholic acid (DHCS) compounds, novel 7ß-hydroxysteroid dehydrogenase mutants, to the sequences encoding said enzyme mutants, to methods for producing the enzyme mutants and to the use thereof in enzymatic conversion of cholic acid compounds, and especially in the production of ursodeoxycholic acid (UDCS); The invention also relates to novel methods for the synthesis of UDCS using the enzyme mutants; and in particular to a further improved method for producing UDCS using recombined whole-cell biocatalysts.
Abstract:
The present invention relates to a method for cross-linking polypeptide molecules, comprising the step of combining a cross-linking agent and polypeptide molecules in solution under conditions suitable for a cross-linking reaction to occur and to a preparation comprising cross-linked polypeptide molecules obtainable by said method. The present invention further relates to cross-linked polypeptide molecules, wherein said polypeptide molecules are cross-linked by essentially unbranched cross-linking groups comprising at least 40 contiguous atoms. Moreover, the present invention relates to a test chemistry matrix comprising a redox cofactor, an agent capable of eliciting a change in at least one measurable property of an indicator reagent in the presence of redox equivalents, and an indicator reagent, wherein said chemistry matrix further comprises a preparation of cross-linked polypeptide molecules obtainable by the method according to the present invention and/or cross-linked polypeptide molecules according tothe present invention, as well as to a diagnostic test element comprising said test chemistry matrix. The present invention further relates to a preparation of cross-linked polypeptide molecules obtainable by the method according the present invention and/or cross-linked polypeptide molecules according to the present invention for use in the diagnosis of disease and for use in diagnosis of diabetes, as well as to a method for producing a test chemistry matrix.
Abstract:
The invention relates to suitable screening strategies for evaluating various candidate promoters for differential gene expression during the propagation and production phases of a fermentation process. The invention also relates to recombinant host cells that comprise identified promoter nucleic acid sequences and methods for producing fermentation products employing the same.
Abstract:
The present invention provides a process for production of optically pure quinuclidinol of formula-(I) by reduction of quinuclidinone of formula-(Il) in presence of suitable oxidoreductase enzyme derived from Saccharomyces species . Formula (II, I) Moreover, the present enzyme works in presence of cofactor NADP where the cofactor is regenerated by suitable system. The present invention also provides a recombinant vector containing genes co expressing suitable polypeptides having oxido-reductase activity and polypeptide having capacity to regenerate the co-factor. The said vector is transformed in suitable host cell.
Abstract:
The present invention is to provide a preparation of variant recombinant whole cell biocatalysts, referred herein as "designer cells" having significantly enhanced carbonyl reductase activity for use in the efficient production of variant industrially important enantiomerically enriched alcohols. More specifically, the alcohol is optically pure ethyl (S)-4-chloro-3-hydroxybutyrate, which is useful as chiral building block and an intermediate for the production of hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitors.